top of page

Overview

Critical Innovations is currently developing multiple medical devices toward regulatory clearance. The company focuses on task-shifting evidence-based interventions to earlier echelons of care and more general specialty levels, to simplify management and allow for rapid provision in emergency and combat environments. To date, the company has worked under more than 20 different Department of Defense awards from all three military branches charged with medical technology development (i.e. U.S. Army, Air Force, and Navy), including such agencies as the Air Force Medical Support Agency; Army Medical Research and Development Command; Defense Health Agency; and, Office of Naval Research. Contract types have included Small Business Innovation Research (SBIR), Joint Warfighter, and Other Transactional Authority. As a prime contractor, Critical Innovations currently has a 100% transition rate from Phase I to Phase II, as well as Phase II to Phase III, for all eligible SBIR programs.

Our Devices

Critical Innovations
- Feb 5, 2021
- 1 min read

PleuraPath™ Thoracostomy System shown to be 19% more effective at blood removal

A recent article in the Journal of Thoracic Disease shows significant improvement in blood removal using the PleuraPath™ Thoracostomy System, when compared to a traditional chest tube, in a large-animal model of retained hemothorax. For most serious chest trauma, tube thoracostomy is the definitive treatment. However, traditional chest tubes fail to sufficiently remove blood in up to one-fifth of patients. This is the first published scientific paper describing the new and innovative PleuraPath™ Thoracostomy System. See full article here.

PleuraPath™ Thoracostomy System shown to be 19% more effective at blood removal

Recent Posts